title: Inflammatory breast cancer: results of antracycline-based neoadjuvant chemotherapy.
abstract: Twenty-three patients with inflammatory breast cancer treated with a combined modality approach including anthracycline-based induction chemotherapy-surgery-chemotherapy-radiotherapy were reviewed. Twelve patients (52.2%) received FAC (5-fluorouracil, adriamycin, cyclophosphamide) and 11 patients (47.8%) were treated with FEC (5-fluorouracil, epirubicin, cyclophosphamide) induction chemotherapy for three cycles every 3 weeks. Surgery was followed by the initial chemotherapy or second-line chemotherapy for an additional six cycles to complete nine cycles and radiotherapy, respectively. The median overall survival (OS) time was 27 months and the median disease-free survival (DFS) was 13 months. Furthermore, patients treated with FAC induction chemotherapy have been found to have longer median OS and DFS periods compared to patients with FEC induction chemotherapy in both univariate and multivariate analysis. In conclusion, the superiority of doxorubicin-containing chemotherapy over epirubicin-containing chemotherapy should be established in larger randomized studies and more effective chemotherapeutic agents such as taxans are required for better survival rates in inflammatory breast cancer patients.
authors.affiliation: Department of General Surgery, Istanbul Faculty of Medicine, University of Istanbul, Istanbul, Turkey. vozmen@istanbul.edu.tr
authors.forename: Vahit
authors.initials: V
authors.lastname: Ozmen
authors.forename: Neslihan
authors.initials: N
authors.lastname: Cabioglu
authors.forename: Abdullah
authors.initials: A
authors.lastname: Igci
authors.forename: Temel
authors.initials: T
authors.lastname: Dagoglu
authors.forename: Adnan
authors.initials: A
authors.lastname: Aydiner
authors.forename: Mustafa
authors.initials: M
authors.lastname: Kecer
authors.forename: Yavuz
authors.initials: Y
authors.lastname: Bozfakioglu
authors.forename: Maktav
authors.initials: M
authors.lastname: Dinçer
authors.forename: Ayhan
authors.initials: A
authors.lastname: Bilir
authors.forename: Erkan
authors.initials: E
authors.lastname: Topuz
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D012074:Remission Induction; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D000903:Antibiotics, Antineoplastic; D015251:Epirubicin; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil